The all time closing high is $58.38. With major competition in all sectors, MSFT is less likely to be slowed by antitrust problems. The new leadership understands MSFT's potential. New highs should be reached by the end of summer.
Of course Imetelstat (IMET) has to continue as an effective, safe, life saving medicine, as it has been since Dr. Tefferi started the MF trials at Mayo Clinic. That has not changed, and will not change. The new trials, under the direction of JNJ/Janssen and Mayo Clinic, are designed to find the ultimate use of IMET, first in the blood cancer cousins (MF, AML, MDS) and eventfully in all cancers. IMET can be used alone or in combination with other drugs. JNJ/Janssen will protect IMET from short-term market forces. Geron is a partner that will benefit by JNJ's actions, but JNJ is calling the "shots".
Imetelstat (IMET) has already been established as a "good" medicine in a basket of blood cancer trials. The new trials, that are now being organized globally by JNJ/Janssen and Mayo Clinic, may allow IMET to obtain "great" status or even "miracle" status. Geron, as a partner of JNJ, is not totally immune to market forces, but is now reasonable well insulated from them. Today was a day when many biotech stocks were "hit". We will see what tomorrow will bring.
"potential to work with ALL mutations/genetic profiles". (Irish).
"POTENTIAL" to work in "ALL" means, IMO, that it should be tried in MANY situations that appear to show promise, including combination medicines. We have no idea, at this point in time, if IMET is just a good drug, or if it is a miracle drug.
Geron appears to be the "leader of the pack" with the telomere-telomerase interactions that may be important in all cancers in addition to the blood cancers, where they have already been successful. I am not familiar with these other names, but I am sure, that if they have anything substantial to offer, JNJ/Janssen will make sure, that they are used in combination with Imetelstat. Shoenfield or anybody: What drugs, from the above companies, seem to offer the most potential, in your opinion?
"I think we are at a turning point". (from Irish). All medical data and scientific theory appears to be pointing to this. The FDA now understands the power of Imetelstat (IMET), and JNJ/Janssen has the resources and global presence to conduct and explain the studies and trials (old & new) globally, with the Mayo Clinic at the epicenter.
The biggest mystery, in my mind, is why advanced approval has not happened yet. The FDA knows patients' needs, and what is currently available. Geron as a small, perhaps confused, biotech company tried, but needed a major partner (JNJ/Janssen) to make progress. It is all happening now, a bit late.
I do remember. In retrospect that would likely have been a better plan, and would have taken the FDA out of the loop.
(IMET HAS HAD) " fair share of safety concerns over the past year and change, but it could also transform myelofibrosis treatment as we know it."
There are no longer any significant "Safety Concerns", and IMET is a "Transformative Medicine". Those are settled issues.
1. Janssen has chosen to start Phase ii testing overseas because................................. You fill in the dots.
Janssen does not want to be totally dependent on the FDA. Approvals often happen in Europe or Asia before the USA, where there is more red-tape. Janssen wishes to have an international footprint for IMET. There are many opportunities for combination drugs, such as the AML studies in Australia.
2. Janssen has not yet selected any U. S. sites because........................... You fill in the dots.
Janssen and Mayo Clinic both have vested interests in IMET, and through Dr. Tefferi are working closely together. Mayo Clinic, with Janssen, will chose the sites in the US.
I agree with you. We should not nominate or elect Obama for a 3rd term. After all George Washington was only elected for 2 terms, which set the legal limit. FDR was illegally elected 4 times, which caused the USA to lose WWII to Russia. Cuba will become the 51st state, and we will have a "Castro" presidency.
There is a strong relationship between cancer stem cell, and human embryonic stem cells.
JNJ/Janssen and Mayo Clinic both continue to support Imetelstat (IMET), as "Tantamount to a Cure" in MF, and that has now progressed to new MDS and AML trials, the other blood cancer cousins. The FDA certainly knows all of this, including the proven safety of IMET. The "milestones" will be passed very soon. FDA advanced approval is in the wind.
It is "slowly" becoming obvious to all that IMET really is a "remarkable-miracle-tantamount-remission-life saving" cancer drug, and the JNJ/Janssen partnership was the catalyst that Geron needed.
"The FDA has every reason to grant advanced approval for IMET" (patients' needs, safety, effectiveness, uniqueness, saves lives). JNJ has ever reason to ask. Geron is now a bystander, that is enjoying the action, and benefitting.
The "game" that the short-hedge-funds are playing is almost over, as they are about to be overwhelmed by superior forces. JNJ has every reason to ask for advanced approval for IMET, and the FDA has every reason to grant it.
Science (Nobel Prize) and Medical Successes from Mayo Clinic, are being noticed by the investment public. JNJ/Janssen is the new, critical factor in Imetelstat credibility.